Meeder Asset Management Inc. purchased a new stake in shares of Haemonetics Co. (NYSE:HAE) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 4,067 shares of the medical instruments supplier’s stock, valued at approximately $512,000.
A number of other large investors have also recently modified their holdings of HAE. Marshall Wace North America L.P. raised its holdings in Haemonetics by 181.1% in the first quarter. Marshall Wace North America L.P. now owns 6,859 shares of the medical instruments supplier’s stock worth $600,000 after buying an additional 4,419 shares during the last quarter. WINTON GROUP Ltd purchased a new position in Haemonetics in the second quarter worth about $3,673,000. Retirement Systems of Alabama raised its holdings in Haemonetics by 0.3% in the second quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock worth $8,015,000 after buying an additional 205 shares during the last quarter. Sheets Smith Wealth Management purchased a new position in Haemonetics in the second quarter worth about $598,000. Finally, Welch & Forbes LLC purchased a new position in Haemonetics in the second quarter worth about $241,000. 99.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of HAE stock opened at $127.25 on Monday. The company has a 50 day moving average price of $127.19 and a 200-day moving average price of $113.92. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $140.36. The firm has a market capitalization of $6.45 billion, a PE ratio of 53.24, a P/E/G ratio of 3.05 and a beta of 0.79. The company has a quick ratio of 1.34, a current ratio of 2.10 and a debt-to-equity ratio of 0.54.
Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.18. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. The firm had revenue of $238.50 million during the quarter, compared to analyst estimates of $236.82 million. During the same period in the previous year, the business posted $0.59 earnings per share. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. Analysts anticipate that Haemonetics Co. will post 3.09 earnings per share for the current year.
HAE has been the subject of several recent analyst reports. Raymond James lifted their target price on shares of Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Jefferies Financial Group lifted their price target on shares of Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Barrington Research reiterated an “outperform” rating and issued a $139.00 price target (up from $116.00) on shares of Haemonetics in a research note on Wednesday, August 7th. Morgan Stanley lifted their price target on shares of Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, JMP Securities lifted their price target on shares of Haemonetics to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $144.40.
In related news, CFO William P. Mr. Burke sold 18,950 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $122.34, for a total transaction of $2,318,343.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Simon sold 50,869 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $137.43, for a total transaction of $6,990,926.67. The disclosure for this sale can be found here. Insiders sold 91,964 shares of company stock valued at $12,077,055 over the last quarter. Company insiders own 1.32% of the company’s stock.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More: Preferred Stock
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.